Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in diastolic dysfunction of metabolic syndrome
2013-002269-21Phase 2Completed
- Sponsor
- Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of metformin in diastolic dysfunction and cardiometabolic risk (CMR) (2 arms), sponsored by Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto. Primary endpoint: Change in early diastolic mitral annular velocity. Started Jun 2013; status: completed.
02
Drugs
metformin
03
Conditions
diastolic dysfunctioncardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2013-002269-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002269-21.